Ask AI
HER2 Targeted ADCs AE Management

CME

HER2-Targeted ADCs in Genitourinary, Gastrointestinal, and Gynecological Malignancies: Safety and Adverse Event Management

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: September 03, 2025

Expiration: March 02, 2026

Activity

Progress
1
Course Completed

References

  1. US Food and Drug Administration. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2. Accessed September 2, 2025. April 2024.
  2. Meric-Bernstam F, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024;42:47-58.
  3. Meric-Bernstam F, et al. Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results. J Clin Oncol. 2023;41. Abstract LBA3000.
  4. Powell CA, et al. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open. 2022;7:100554. 
  5. Rugo S, et al. Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis. Ann Oncol. 2025;[Epub ahead of print].
  6. Trastuzumab deruxtecan [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo, Inc.; 2025.
  7. Soares LR, et al. Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis. ESMO Open. 2023;8:101613.
  8. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: antiemesis. v.2.2025. nccn.org. Accessed September 2, 2025.
  9. National Medical Products Administration approves injection of Disitamab Vedotin treatment of HER2-positive advanced breast cancer with liver metastases in China [press release]. RemeGen Co., Ltd.; 2025.
  10. Sheng X, et al. Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials. JCO. 2024;42:1391.